Insulin analogues and their potential in the management of diabetes mellitus

Diabetologia

Volumn 42, Issue 10, 1999, Pages 1151-1167

  Bolli, G B ^a   Di Marchi, R D ^b   Park, G D ^c   Pramming, S ^d   Koivisto, V A ^e  

^a UNIVERSITY OF PERUGIA   (Italy)

^b ELI LILLY AND COMPANY   (United States)

^c SANOFI   (France)

^d NOVO NORDISK A S   (Denmark)

^e Lilly Research Laboratories   (Germany)

Author keywords

Continuous subcutaneous insulin infusion; Insulin analogues; Insulin pharmacodynamics; Insulin pharmacokinetics; Physiologic insulin therapy; Type I diabetes mellitus

Indexed keywords

C 16HI; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SCREENING; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; TOXICITY TESTING;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; DOGS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN; INSULIN, ISOPHANE; SWINE; TIME FACTORS;

EID: 0032819174     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051286     Document Type: Review

References (155)

1. Rizza RA, Gerich JE, Haymond MW et al. (1980) Control of blood sugar in insulin-dependent diabetes:comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion, and intensified conventional therapy. N Engl J Med 303: 1313-1318
2. Reichard P, Nilsson B-Y, Rosenqvist U (1993) The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329: 304-309
3. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986
4. Waldhäusl WK (1986) The physiological basis of insulin treatment. Clinical aspects. Diabetologia 29: 837-849
5. Pampanelli S, Fanelli C, Lalli C et al. (1996) Long-term intensive insulin therapy in IDDM:effects of HbA1c, risk for severe and mild hypoglycaemia, status of counterregulation and awareness of hypoglycaemia. Diabetologia 39: 677-686
6. Fanelli C, Pampanelli S, Epifano L et al. (1994) Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM. Diabetologia 37: 1265-1276
7. Bott S, Bott U, Berger M, Mülhauser I (1997) Intensified insulin therapy and the risk of severe hypoglycaemia. Diabetologia 40: 926-932
8. Mühlhauser I, Overmann H, Bender R, Bott U, Berger M (1998) Risk factors of severe hypoglycaemia in adult patients with Type I diabetes - a prospective population based study. Diabetologia 41: 1274-1282
9. Valle T, Koivisto VA, Reunanen A et al. (1999) Glycemic control in patients with diabetes in Finland. Diabetes Care 22: 575-579
10. Dimitriadis GD, Gerich JE (1983) Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 6: 374-377
11. Ciofetta M, Lalli C, Del Sindaco P et al. (1999) Contribution of postprandial versus interprandial blood glucose to HbA1c in Type I diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 22:795-800
12. Barnett AH, Owens DR (1997) Insulin analogues. Lancet 349: 47-51
13. Holleman F, Hoekstra JBL (1997) Insulin lispro. N Engl J Med 337: 176-183
14. Lee WL, Zinman B (1998) From insulin to insulin analogs:progress in the treatment of Type I diabetes. Diabetes Rev 6: 73-88
15. Emdin SO, Dodson GG, Cutfield JM, Cutfield SM (1980) Role of zinc in insulin biosynthesis. Some possible zinc-insulin interactions in the pancreatic B-cell. Diabetologia 19: 174-182
16. Brange J, Ribel U, Hansen JF et al. (1988) Monomeric insulins obtained by protein engineering and their medical implications. Nature 333: 679-682
17. Drejer K, Kruse V, Larsen UD et al. (1991) Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes 40: 1488-1495
18. Blundell T, Dodson G, Hodgkin D, Mercola D (1972) Insulin:the structure in the crystal and its reflection in chemistry and biology. Adv Protein Chem 26: 279-402
19. Binder C, Lauritzen T, Faber O, Pramming S (1984) Insulin pharmacokinetics. Diabetes Care 7: 188-199
20. Hildebrandt P, Sestoft L, Nielsen SL (1983) The absorption of subcutaneously injected short-acting soluble insulin:influence of injection technique and concentration. Diabetes Care 6: 459-462
21. Brange J, Owens DR, Kang S, Vølund A (1990) Monomeric insulins and their experimental and clinical implications. Diabetes Care 13: 923-954
22. Di Marchi RD, Chance RE, Long HB, Shields JE, Slieker LJ (1994) Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I. Horm Res 41[Suppl 2]:S93-S96
23. Brems DN, Alter LA, Beckage MJ et al. (1992) Altering the association properties of insulin by amino acid replacement. Protein Eng 5: 527-533
24. Wiefels K, Kuglin B, Hübinger A, Jorgensen LN, Gries FA (1993) Insulin kinetics and dynamics in insulin-dependent diabetic patients after injections of human insulin or the insulin analogues X14 and X14 + Zn. In: Berger M, Gries FA (eds) Frontiers in Insulin Pharmacology. Thieme, Stuattgart, pp 97-101
25. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR (1994) [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 43: 396-402
26. Kang S, Brange J, Butch A, Vølund A, Owens DR (1991) Subcutaneous insulin absorption explained by insulin's physicochemical properties. Evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care 14: 942-948
27. Vølund A, Brange J, Drejer K et al. (1991) In vitro and in vivo potency of insulin analogues designed for clinical use. Diabet Med 8: 839-847
28. Kang S, Brange J, Burch A, Vølund A, Owens DR (1991) Absorption kinetics and action profiles of subcutaneously administrated insulin analogues (AspB9, GluB27; AspB10; AspB28) in healthy subjects. Diabetes Care 14: 1057-1065
29. Jørgensen LN, Dideriksen LH (1993) Preclinical studies of rapid-acting insulin analogues. In: Berger M, Gries FA (eds) Frontiers in insulin pharmacology. Thieme, Stuttgart, pp 110-117
30. Drejer K (1992) The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 8: 259-285
31. Di Marchi R, Long H, Epp J, Schoner B, Belagaje R (1989) Synthesis of insulin-like growth factor I through recombinant DNA techniques and selective chemical cleavage at tryptophan. In: Tam JP, Kaiser ET (eds) Synthetic peptides:approaches to biological problems. Liss, New York, pp 283-294
32. Slieker LJ, Brooke GS, Di Marchi RD et al. (1997) Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 40[Suppl 2]:S54-S61
33. Radziuk JM, Davies JC, Pye WS et al. (1997) Bioavailability and bioeffectiveness of subcutaneous human insulin and two of its analogs - LysB28, ProB29-human insulin and AspB10, LysB28,ProB29-human insulin - assessed in a conscious pig model. Diabetes 46: 548-556
34. Somwar R, Sweeney G, Ramlal T, Klip A (1998) Stimulation of glucose and amino acid transport and activation of the insulin signaling pathways by insulin lispro in L6 skeletal muscle cells. Clin Ther 20: 125-140
35. Zimmermann JL, Truex LL (1997) A 12-month chronic toxicity study of LY275 585 (human insulin analog) administered subcutaneously to Fischer 344 rats. Int J Toxicol 16: 639-657
36. Buelke-Sam J, Byrd RA, Hoyt JA, Zimmermann JL (1994) A reproductive and developmental toxicity study in CD rats of LY275 585 [Lys(B28, Pro(B29)]-human insulin. J Am Coll Toxicol 13: 247-260
37. Zwickl CM, Smith HW, Zirmnermann JL, Wierda D (1995) Immunogenicity of biosynthetic human LysPro insulin compared to native-sequence human and purified porcine insulins in rhesus monkeys immunized over a 6-week period. Arzneimittelforschung 45 (I): 524-528
38. Anderson JH Jr, Brunelle RL, Koivisto VA et al. (1997) Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clin Ther 19: 62-72
39. Anderson JH Jr, Brunelle RL, Koivisto VA et al. (1997) Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes 46: 265-270
40. Anderson JH Jr, Brunelle RL, Keohane P et al. (1997) Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Int Med 157: 1249-1255
41. Zinman B, Tildesley H, Chiasson J-L, Tsui E, Strack T (1997) Insulin lispro in CSII. Results of a double-blind cross-over study. Diabetes 46: 440-443
42. Melki V, Renard E, Lassmann-Vague V et al. (1998) Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care 21: 977-982
43. De Verga V, Ristic S, and the Ramadan Study Group (1998) Insulin lispro therapy during Ramadan fasting. Diabetes 47[Suppl 1]:A105 (Abstract)
44. Garg SK, Anderson JH, Perry SV et al. (1999) Long-term efficacy of Humalog® in subjects with Type I diabetes mellitus. Diabet Med 16: 384-387
45. Schernthaner G, Wein W, Sandholzer K et al. (1998) Post-prandial insulin lispro. A new therapeutic option for Type I diabetic patients. Diabetes Care 21: 570-573
46. Holleman F, van den Brand JJG, Hoven RARA et al. (1996) Comparison of LysB28, ProB29-human insulin analog and regular human insulin in the correction of incidental hyper-glycemia. Diabetes Care 19: 1426-1429
47. Attia N, Jones TW, Holcombe J, Tamborlane WV (1998) Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and the treatment of acutely decompensated IDDM. Diabetes Care 21: 817-821
48. Guerci B, Meyer L, Sailé A et al. (1999) Comparison of metabolic deterioration beteween insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in Type I diabetic patients. J Clin Endocrinol Metab 84: 2673-2678
49. Torlone E, Pampanelli S, Lalli C et al. (1996) Effects of short-acting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM. Diabetes Care 19: 945-952
50. Ahmed ABE, Home PD (1998) The effect of the insulin analog lispro on nighttime blood glucose control in Type I diabetic patients. Diabetes Care 21: 32-37
51. Del Sindaco P, Ciofetta M, Lalli C et al. (1998) Use of the short-acting insulin analogue lispro in intensive treatment of Type I diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med 15: 592-600
52. Ahmed ABE, Mallias J, Home PD (1998) Optimization of evening insulin dose in patients using the short-acting insulin analog lispro. Diabetes Care 21: 1162-1166
53. Ahmed ABE, Home PD (1998) Optimal provision of daytime NPH insulin in patients using the insulin analog lispro. Diabetes Care 21: 1707-1713
54. Ebeling P, Jansson P-A, Smith U et al. (1997) Strategies toward improved control during insulin lispro therapy in IDDM: importance of basal insulin. Diabetes Care 20: 1287-1289
55. Jansson P-A, Ebeling P, Smith U et al. (1998) Improved glycemic control can be better maintained with insulin lispro than with human regular insulin. Diab Nutr Metab 11: 194-199
56. Colombel A, Murat A, Krempf M et al. (1999) Improvement of blood glucose control in Type I diabetic patients treated with lispro and multiple NPH injections. Diabet Med 16: 319-324
57. Lalli C, Ciofetta M, Del Sindaco P et al. (1999) Long-term intensive treatment of Type I diabetes with the short-acting insulin analogue lispro in variable combination with NPH insulin at mealtime. Diabetes Care 22: 468-477
58. Rennet R, Pfützner A, Trautmann M et al. (1999) Use of insulin lispro in continuous subcutaneous insulin infusion treatment: results of a multicenter trial. Diabetes Care 22: 784-788
59. Chase HP, Peery BN, Sheperd ME et al. (1999) The impact of the DCCT and of Humalog treatment on glycohemoglobin (HbA1c) and hypoglycemia in Type I diabetes. Diabetes 48[Suppl 1]: A100 (Abstract)
60. The Diabetes Control and Complications Trial Research Group (1996) The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 45: 1289-1298
61. Pfützner A., Küstner E., Forst T. et al. (1996) Intensive insulin therapy with insulin lispro in patients with Type I diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol Diabetes 104: 25-30
62. Burge MR, Castillo KR, Schade DS (1997) Meal composition is a determinant of lispro-induced hypoglycemia in IDDM. Diabetes Care 20: 152-155
63. Torlone E, Fanelli C, Rambotti AM et al. (1994) Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia 37: 713-720
64. McCrimmon RJ, Frier BM (1997) Symptomatic and physio-logical responses to hypoglycaemia induced by human soluble insulin and the analogue lispro human insulin. Diabet Med 14: 929-936
65. Bolli GB (1997) Hypoglycaemia unawareness. Diabetes Metab 23[Suppl 3]:S29-S35
66. Janssen MMJ, Masurel M, Hoogma RPLM et al. (1998) Effects of multiple injection therapy with lispro high mix insulin on the catecholamine response to hypoglycaemia. Diabetologia 41[Suppl 1]:A244 (Abstract)
67. Brunelle RL, Llewelyn J, Anderson JH Jr, Gale EAM, Koivisto VA (1998) Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with Type 1 diabetes. Diabetes Care 21: 1726-1731
68. Holleman F, Schmitt H, Rottiers R et al. (1997) Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. Diabetes Care 20: 1827-1832
69. Launay B, Zinman B, Tildesley HD, Strack T, Chiasson J-L (1998) Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes. Diabetes Care 21: 1627-1631
70. Anderson JH Jr, Koivisto VA (1998) Clinical studies on insulin lispro. Drugs of Today 34[Suppl C]:37-50
71. Tuominen JA, Karonen S-L, Melamies L, Bolli G, Koivisto VA (1995) Exercise-induced hypoglycemia in IDDM patients treated with a short-acting insulin analogue. Diabetologia 38: 106-111
72. Rönnemaa T, Viikari J (1998) Reducing snacks when switching from conventional soluble to lispro insulin treatment:effects on glycaemic control and hypoglycaemia. Diabet Med 15:601-607
73. Binder C (1969) Absorption of injected insulin. A clinical-pharmacological study. Acta Pharmacol Toxicol (Copenh) 27[Suppl 2]: 1-84
74. ter Braak EW, Woodworth JR, Bianchi R et al. (1996) Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 19: 1437-1440
75. Fineberg NS, Fineberg SE, Anderson JH et al. (1996) Immunologic effects of insulin lispro [Lys(B28), Pro(B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes 45: 1750-1754
76. Lahtela JT, Knip M, Paul R, Antonen J, Salmi J (1997) Severe antibody-mediated human insulin resistance:successful treatment with the insulin analog lispro. Diabetes Care 20: 71-73
77. Henrichs HR, Unger H, Trautmann ME, Pfützner A (1996) Severe insulin resistance treated with insulin lispro. Lancet 348: 1248
78. Kumar D (1997) Lispro analog for treatment of generalized alleregy to human insulin. Diabetes Care 20: 1357-1359
79. Meier M, Brand J, Standl E, Schnell O (1998) Successful treatment with insulin analog lispro in IDDM with delayed absorption of subcutaneously applied human regular insulin and complicated intraperitoneal insulin infusion. A case report. Diabetes Care 21: 1044-1045
80. Kotsanos JG, Vignati L, Huster W et al. (1997) Health-related quality-of-life results from multinational clinical trials of insulin lispro. Diabetes Care 20: 948-958
81. Bastyr EJ III, Holcombe JH, Anderson JH, Clore JN (1997) Mixing insulin lispro with ultralente insulin. Diabetes Care 20: 1047-1048
82. Joseph SE, Korzon-Burakowska A, Woodworth JR et al. (1998) The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. Diabetes Care 21: 2098-2102
83. Zinman B, Ross S, Campos RV et al. (1999) Effectiveness of human ultralente versus NPH insulin in providing basal insulin replacement for an insulin lispro multiple daily injection regimen. Diabetes Care 22: 603-608
84. Pampanelli S., Torlone E., Lalli C. et al. (1995) Improved post-prandial metabolic control after subcutaneous injection of a short acting insulin analogue in IDDM of short duration with residual pancreatic beta cell function. Diabetes Care 18: 1452-1459
85. Heinemann L, Heise T, Wahl LC et al. (1996) Prandial glycaemia after a carbohydrate-rich meal in Type I diabetic patients:using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med 13: 625-629
86. Holcombe JH, Brunelle R, Zalani S, Deeb LC (1998) Comparative study of insulin lispro and regular insulin in prepubertal children with type 1 diabetes. Diabetes 47[Suppl 1]:A96 (Abstract)
87. Rutledge KS, Chase HP, Klingensmith GJ et al. (1997) Effectiveness of postprandial Humalog in toddlers with diabetes. Pediatrics 100: 968-972
88. Wallensteen M, Dahlquist G, Persson B et al. (1988) Factors influencing the magnitude, duration and the rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis. Diabetologia 31: 664-669
89. Jovanovic L, Ilic S, Pettit DJ et al. (1999) The metabolic and immunological effects of insulin lispro in gestational diabetes. Diabetes Care 22: 1422-1427
90. Garg SK, Pennington M, Gottlieb P et al. (1999) Comparison of maternal and fetal outcomes between human regular and Humalog® insulin treated pregnancies in type 1 diabetes. Diabetes 48[Suppl 1]:A61(Abstract)
91. Kitzmiller JL, Main E, Ward B et al. (1999) Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy. Diabetes Care 22: 874-875
92. Jovanovic L (1999) Retinopathy risk:what is responsible? Hormones, hyperglycemia, or Humalog? Response to Kitzmiller et al. Diabetes Care 22: 846-848
93. Torlone E, Lalli C, Del Sindaco P et al. (1999) Optimization of postprandial blood glucose with lispro insulin in T2DM. Diabetes 48[Suppl 1]:A357 (Abstract)
94. Feinglos MN, Thacker CH, English J, Bethel MA, Lane JD (1997) Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 20: 1539-1542
95. Bruttomesso D, Pianta A, Mari A et al. (1999) Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 48: 99-105
96. Kang S, Creagh FM, Peters JR et al. (1991) Comparison of subcutaneous soluble human insulin and insulin analogues (AspBg, GluB27; AspB10; AspB28) on meal-related plasma glucose excursions in type 1 diabetic subjects. Diabetes Care 14: 571-577
97. Brange J, Vølund A (1999) Insulin analogs with improved pharmacokinetic profile. Adv Drug Delivery Rev 35: 307-335
98. Owens DR, Kang S, Luzio S, Coates P (1993) Clinical results of phase I studies with insulin analogues. In: Berger M, Gries FA (eds) Frontiers in insulin pharmacology. Thieme, Stuttgart, pp 79-86
99. Hansen BF, Danielsen GM, Drejer K et al. (1996) Sustained signalling from the insulin receptor after stimulation with insulin analogues exibiting increased mitogenic potency. Biochem J 315: 271-279
100. Jørgensen LN, Didriksen LH (1993) Preclinical studies of rapid-acting insulin analogues. In: Berger M, Gries FA (eds) Frontiers in insulin pharmacology. Thieme, Stuttgart, pp 110-117
101. Ottesen JL, Nilsson P, Jami J et al. (1994) The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 37: 1178-1185
102. Heinemann L, Heise T, Jorgensen LN, Starke AAR (1993) Action profile of the rapid acting insulin analogue:human insulin B28Asp. Diabet Med 10: 535-539
103. Home P, Barriocanal L, Lindholm A (1999) Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 55: 199-203
104. Heinemann L, Weyer C, Rauhaus M, Heinrich S, Heise T (1998) Variability of the metabolic effects of soluble insulin and the rapid acting insulin analogue insulin aspart. Diabetes Care 21: 1914-1919
105. Lindholm A, McEwen J, Riis AP (1999) Improved postprandial glycemic control with insulin aspart:a randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 22: 801-805
106. Home PD, Lindholm A, Hylleberg B, Round P, for the UK Insulin Aspart Study Group (1998) Improved glycaemic control with Insulin Aspart - a multicentre randomized, double-blind cross-over trial in type 1 diabetic patients. Diabetes Care 21: 1904-1909
107. Home PD, Lindholm A, Riis AP, For The European Insulin Aspart Study Group (1999) Improved long-term blood glucose control with insulin aspart versus human insulin in people with type 1 diabetes. Diabetes 48[Suppl 1]:A358(Abstract)
108. Nielsen FS, Jørgensen LN, Ipsen M, Voldsgaard AI, Parving H-H (1995) Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia 38: 592-598
109. Jacobs MAJM, Keulen ETP, Kanc K et al. (1997) Metabolic efficacy of preprandial administration of Lys(B28),Pro(B29) human insulin analog in IDDM patients. Diabetes Care 20: 1279-1286
110. Raskin P, McGill J, Kilo C, Boss AH (1999) Human insulin analog (Insulin Aspart, IAsp) is comparable to human insulin in type 2 diabetes. Diabetes 48[Suppl 1]:A355(Abstract)
111. Rosenfalck AM, Thorsby P, Kjems L et al. (1999) Effects of the rapid-acting insulin analogue insulin aspart on postprandial glycaemic excursions compared to human soluble insulin actrapid given immediately or 30 minutes before a meal in insulin treated type 2 diabetes patients. Diabetes 48[Suppl 1]:A116(Abstract)
112. Halberg IB, Jacobsen LV, Dahl UL (1999) A study on self-mixing insulin aspart with NPH insulin in the syringe before injection. Diabetes 48[Suppl 1]:A104(Abstract)
113. Ceriello A (1998) The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabet Med 15: 188-193
114. Perriello G, De Feo P, Torlone E et al. (1991) The dawn phenomenon in Type 1 (insulin-dependent) diabetes mellitus:magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity. Diabetologia 34: 21-28
115. Perriello G, De Feo P, Torlone E et al. (1990) Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in Type I (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia 33: 52-59
116. Koivisto VA, Yki-Järvinen H, Helve E, Karonen S-L, Pelkonen R (1986) Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. Diabetes 35: 78-82
117. Bolli GB, Perriello G, Fanelli CG, De Feo P (1993) Nocturnal blood glucose control in type 1 diabetes mellitus. Diabetes Care 16[Suppl 3]:S71-S89
118. Bolli GB (1999) How to ameliorate the problem of hypoglycemia in intensive as well as non-intensive treatment of type 1 diabetes. Diabetes Care 22[Suppl 2]:B43-B52
119. Pramming S, Thorsteinsson B, Bendtson I, Ronn B, Binder C (1985) Nocturnal hypoglycaemia in patients receiving conventional treatment with insulin. BMJ 291: 376-379
120. Fanelli CG, Paramore DS, Hershey T et al. (1998) Impact of nocturnal hypoglycemia on hyupoglycemic cognitive dysfunction in type 1 diabetes. Diabetes 47: 1920-1927
121. Veneman T, Mitrakou A, Mokan M, Cryer P, Gerich J (1993) Induction of hypoglycemia unawareness by asymptomatic nocturnal hypoglycemia. Diabetes 42:1233-1237
122. Kanc K, Janssen MMJ, Keulen ETP et al. (1998) Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM. Diabetologia 41: 322-329
123. Jones TW, Porter P, Sherwin RS et al. (1998) Decreased epinephrine response to hypoglycemia during sleep. N Engl J Med 338:1657-1662
124. Perriello G, De Feo P, Torlone E et al. (1988) The effect of asymptomatic nocturnal hypoglycemia on glycemic control in diabetes mellitus. N Engl J Med 319:1233-1239
125. Fowelin J, Attvall S, von Schenck H, Smith U, Lager I (1990) Postprandial hyperglycaemia following a morning hypoglycaemia in Type I diabetes mellitus. Diabet Med 7:156-161
126. Markussen J, Hougaard P, Ribel U, Sørensen AR, Sørensen E (1987) Soluble prolonged-acting insulin derivatives. I. Degree of protraction and crystallizability of insulins substituted in the termini of the B-chain. Protein Eng 1:205-213
127. Markussen J, Havelund S, Kurtzhals P et al. (1996) Soluble fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39:281-288
128. Galloway JA, Hooper SA, Spradlin CT et al. (1992) Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care 15:666-692
129. Heinemann L, Heise T, Klepper A et al. (1995) Time-action profiles of the intermediate-acting insulin analogue des(64,65)-human proinsulin. Diabetes Metab 21:415-419
130. Jørgensen S, Vaag A, Langkjaer L, Hougaard P, Markussen J (1989) NovoSol Basal:pharmacokinetics of a novel soluble long acting insulin analog. BMJ 299:415-419
131. Bäihr M, Kolter T, Seipke G, Eckel J (1997) Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells. Eur J Pharmacol 320:259-265
132. Berti L, Kellerer M, Bossenmaier B et al. (1998) The long acting human insulin analog HOE 901:charcteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm Metab Res 30:123-129
133. Dreyer M, Pein M, Schmidt C et al. (1994) Comparison of the pharmacokinetics/dynamics of Gly(A21)-Arg(B31,B32)-human-insulin (HOE71GT) with NPH-insulin following subcutaneous injection by using euglycaemic clamp technique. Diabetologia 37[Suppl 1]:A78(Abstract)
134. Lepore M, Kurzhals R, Pampanelli S et al. (1999) Pharmacokinetics and dynamics of s.c. injection of the long-acting insulin glargine (HOE901) in T1DM. Diabetes 48[Suppl 1]:A97(Abstract)
135. Luzio SD, Owens D, Evans M et al. (1999) Comparison of the s.c. absorption of HOE 901 and NPH human insulin in type 2 diabetic subjects. Diabetes 48[Suppl 1]:A111 (Abstract)
136. Owens D, Luzio S, Tinbergen J, Kurzhals R (1998) The absorption of HOE 901 in healthy subjects. Diabetologia 41[Suppl 1]:A245(Abstract)
137. Talaulicar M, Willms B, Rosskamp R (1996) HOE 901, ein neues insulinanalogon, zur substitution des basalen insulin-bedarfs bei Typ-l-diabetes. Diabetes und Stoffwechsel 5:3-6
138. Pieber T, Eugene-Jolchine I, Derobert E (1998) Efficacy and safety of HOE 901 in patients width type 1 diabetes:a four-week randomised, NPH insulin-controlled trial. Diabetes 47[Suppl 1]:A62(Abstract)
139. Rosenstock J, Park G, Zimmerman J (1998) Efficacy and safety of HOE 901 in patients with type 1 DM:a four-week randomized, NPH insulin-controlled trial. Diabetes 47[Suppl 1]:A92(Abstract)
140. Ratner RE, Hirsch IB, Mecca TE, Wilson CA (1999) Efficacy and safety of insulin glargine in subjects with type 1 diabetes:a 28 week randomized, NPH insulin-controlled trial. Diabetes 48[Suppl 1]:A120(Abstract)
141. Rosenstock J, Schwartz S, Clark C, Edwards M, Donley D (1999) Efficacy and safety of HOE 901 (insulin glargine) in subjects with type 2 DM:a 28-week randomized, NPH insulin-controlled trial. Diabetes 48[Suppl 1]:A100(Abstract)
142. Home P (1999) Insulin glargine:the first clinically useful extended-acting insulin in half a century? Exp Opin Invest Drugs 8:307-313
143. Kurtzhals P, Havelund S, Jonassen I et al. (1995) Albumin binding of insulin acylated with fatty acids:characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 312:725-731
144. Strange P, McGill J, Mazzeo M (1999) Reduced pharmacokinetic (PK) variability of a novel, long-acting insulin analog. Diabetes 48[Suppl 1]:A103(Abstract)
145. Kurtzhals P, Havelund S, Johanssen I, Markussen J (1997) Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. J Pharm Sci 86: 1365-1368
146. Heinemann L, Sinha K, Weyer C et al. (1999) Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med 16:332-338
147. Myers SR, Yakubu-Madus FE, Johnson WT et al. (1997) Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes 46:637-642
148. ε-palmitoyl Lys (B29)] human insulins in subjects with IDDM. Diabetologia 41:116-120
149. ε-palmitoyl Lys (B29)] human insulins in subjects with IDDM. Erratum. Diabetologia 41:489-490
150. Brader ML, Millican RL, Brems DN et al. (1997) Effects of surface hydrophobicity on the structural properties of insulin. In: Marshak DR (ed) Techniques in Protein Chemistry VIII. Academic Press, San Diego, pp 289-297
151. Janssen MMJ, Casteleijn S, Deville W et al. (1997) Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting lispro preparation. Diabetes Care 20:1870-1873
152. Weyer C, Heise T, Heinemann L (1997) Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of rapid-acting insulin analog in stable mixture. Diabetes Care 20:1612-1614
153. Heise T, Weyer C, Serwas A et al. (1998) Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 21:800-803
154. Koivisto VA, Tuominen JA, Ebeling P (1999) Lispro Mix 25 insulin as a premeal therapy in type 2 diabetic patients. Diabetes Care 22:459-462
155. Roach P, Yue L, Arora V, and The Humalog Mix25 Study Group (1999) Improved postprandial glycemic control during treatment with Humalog Mix 25, a novel protamine-based insulin lispro formulation. Diabetes Care 22:1258-1261